Gen5 Plate Reader Setup Guide: ELISA, Luminescence, Fluorescence Assays

ELISA (Enzyme-Linked Immunosorbent Assay) is a solid-phase based assay technique for detecting and quantifying soluble substances like proteins, antibodies, and hormones. The procedure involves immobilizing antigen or antibody on the plastic microplate surface, adding the sample, incubation, washing to remove unbound material, adding enzyme-conjugated antibody/antigen, adding substrate for color development, and reading by colorimetry. Each test run must include at least one full set of controls (internal from manufacturer and external in-house controls prepared from high-titer positive samples). Main analytical errors include improper incubation time or temperature, improper washing, carry-over from adjacent specimens, equipment malfunction, and calculation errors. ELISA advantages include suitability for large sample volumes (100-200+ donations daily), small sample volume required, higher sensitivity than rapid tests, and lower cost for mass testing. Chemiluminescence Immunoassay (CLIA) is a fully automated method using chemiluminescent substrates instead of colorimetric substrates, offering higher throughput, less sample quantity, less time, random sample operation, and higher sensitivity.

Immunoassay labels generate detectable signals through fluorescence (fluorescein), chemiluminescence (luminol, acridium esters), radioisotopes, or enzymes (peroxidase, phosphatase). Labels are chemically bonded to antigens or antibodies during reagent manufacturing. ELISA (Enzyme-Linked Immunosorbent Assay) is a solid-phase immunoassay where antigen or antibody is adsorbed onto microtiter plate wells. Sample addition allows complex formation, followed by washing and enzyme-labeled antibody addition. Substrate addition produces color change proportional to analyte concentration. Types include direct, indirect, and competitive ELISA formats.

ELISA (Enzyme-Linked Immunosorbent Assay) is an immunoenzymatic method for detecting antibodies, antigens, proteins, or glycoproteins in biological samples. The technique uses enzyme-conjugated antibodies that react with chromogenic substrates to produce detectable colored products. Key components include antigens (foreign substances triggering antibody production) and antibodies (immunoglobulins produced by the immune system). Tests are performed in 96-well plates allowing parallel sample processing. Two main approaches exist: direct ELISA where enzyme-conjugated antibodies bind directly to antigens, and indirect ELISA which uses primary antibodies followed by enzyme-conjugated secondary antibodies for signal amplification. Standard curves are essential for quantitative measurements.

Enzyme immunoassays use enzymes (alkaline phosphatase, horseradish peroxidase, beta-galactosidase) as labels. Heterogeneous assays require washing and are used for drugs and hormones; homogeneous assays don't require washing but are less sensitive. ELISA is the most common, used for HIV, hepatitis, and antibody detection. Rapid immunochromatography uses colloidal gold for point-of-care testing. Fluorescent immunoassays are qualitative: direct detects antigen with fluorescent antibody, indirect detects patient antibodies with fluorescent anti-human immunoglobulin. FTA-ABS is used for syphilis. FPIA measures drug concentrations via polarization changes. Chemiluminescent assays use oxidation reactions (luminol, acridinium esters) producing light, used for hormones and therapeutic drugs.

This section covers five major immunoassay types: Radioimmunoassay (RIA), Enzyme-linked immunosorbent assay (ELISA), Chemiluminescence immunoassay, Fluorescence immunoassay, and Competitive immunoassay. The key distinction lies in detection mechanisms: Fluorescence requires external electromagnetic radiation excitation, where substances absorb light and emit at longer wavelengths. Chemiluminescence involves spontaneous light emission from chemical reactions without external radiation. Labeling techniques attach detectable markers (radioactive, enzymatic, fluorescent, or chemiluminescent) to antigens or antibodies, enabling differentiation and quantification of binding interactions in immunological assays.

Spectrophotometry is a technique that measures optical density (OD), defined as the ratio of incident light intensity to transmitted light intensity (OD = I_incident/I_transmitted), which indicates a substance's ability to absorb or resist light; according to Beer-Lambert's law, cell mass and solute concentration are directly proportional to optical density, meaning higher concentrations absorb more light and produce higher OD values, and the spectrophotometer instrument uses a light source, collimator, monochromator with prism, wavelength selector, sample compartment, detector, and display to measure these properties.

The Beer-Lambert Law (A = ε × l × c) describes the linear relationship between absorbance (A) and concentration (c) in spectrophotometry, where A is the absorbance measured by a spectrophotometer, ε is the molar absorptivity (a characteristic property of the substance), l is the path length of light through the sample, and c is the concentration of the absorbing species; this law allows determination of unknown concentrations by measuring absorbance at a specific wavelength and using either direct calculation or graphical methods involving absorbance versus concentration plots.

This section explains how spectrophotometers measure compound concentrations. The Beer-Lambert Law states that absorbance equals negative logarithm of transmittance (A = -log₁₀(T)), and mathematically A = εlc where ε is molar extinction coefficient, l is path length, and c is concentration. The law applies only to dilute solutions below ~10,000 M. Spectrophotometers use deuterium, tungsten, or xenon lamps as light sources, monochromators to select wavelengths, and detectors to measure transmitted light. Sample cells (cuvettes) must be handled carefully to avoid contaminating optical surfaces.

Spectrophotometry measures light absorption to determine solution concentration; the Beer-Lambert Law (A = εbc) states that absorbance (A) is directly proportional to the product of molar absorptivity (ε), path length (b), and concentration (c), enabling quantitative analysis by measuring how much light a solution absorbs at a specific wavelength.

Optical density (absorbance) is defined as A = -log₁₀(T), where T is transmittance. According to Beer-Lambert law, A = εcl, where ε is molar extinction coefficient, c is concentration, and l is path length. For solution A: T = 0.5, so A = -log(0.5) = log(2) = 0.3010. For solution B: using the same compound, A = ε × c × l. Since ε and l are constant, A ∝ c. For solution C: T = 0.1, so A = -log(0.1) = 1.0. The order of optical density is C > A > B.

Proper plate design is essential for quantitative ELISA results. The plate should contain: (1) samples applied in duplicate or triplicate to account for variability; (2) a standard curve prepared from serial dilutions of a known protein (typically BSA) at various concentrations; (3) positive controls with known concentrations to verify assay performance; (4) blank samples containing all reagents except protein to serve as background correction. After completing all assay steps, absorbance is measured for each well. A standard curve plotting absorbance versus concentration allows calculation of unknown sample concentrations. For highly concentrated samples, dilution is necessary before analysis to ensure readings fall within the linear range of the standard curve.

In biochemical and ELISA assays, proper controls are essential for accurate results: blank wells measure background values from buffer and are subtracted from all readings; negative controls confirm assay setup works correctly by omitting antibodies or samples; positive controls validate assay functionality using known analyte quantities; in competitive ELISAs, B0 controls represent maximum color development when no competitor is present, while NSB controls (non-specific binding) show baseline binding without capture antibody; standards serve as pure positive controls with known analyte concentrations; and total activity (TA) controls verify enzymatic activity throughout long incubation periods.

This segment covers the complete PNP standard curve preparation and enzyme assay execution. The instructor demonstrates creating serial dilutions by adding 110 microliters of buffer to wells D2-D5 and E2-E5, then loading 330 microliters of PNP standard into D1 and E1. Serial dilutions are created by transferring 110 microliters from each well to the next, mixing by pipetting up and down, and repeating until the final wells. A blank is created by adding 110 microliters twice to D7 and E7. The instructor then adds 200 microliters of reagent to each well containing enzyme samples, explaining that this volume is sufficient to mix with the 20 microliters of sample without requiring additional mixing. The plate is covered and incubated for 20 minutes before reading on the plate reader.

A standard curve determines unknown substance concentration by comparing to known standards. The experiment has three phases: Phase 1 creates a calibration curve by plotting absorbance against known concentrations. Phase 2 involves serial dilution of unknown protein and concentration determination. Phase 3 plots absorption spectra. The Biuret reagent contains hydrated copper sulfate, sodium hydroxide, and Rochelle salt, reacting with peptide bonds for spectrometric measurement. Six tubes are prepared: one blank (all reagents except protein) and five with varying protein concentrations (0.2-1.0 mL). After incubation, absorbance is measured at 540 nm. Concentration calculations use the stock concentration (10 mg/mL) to determine mg of protein in each tube.

The biuret assay detects peptides using biuret reagent (two coupled urea molecules) and copper tartrate complex under basic conditions. Copper forms a complex with tartrate anions and couples with peptides, requiring at least a three-peptide chain for detection. The experiment uses a spectrophotometer set to 550 nm to measure absorbance. A blank is created by filling a cuvette with water and setting absorbance to zero. Standard curves are prepared by creating a table of protein concentrations ranging from 0 to 10 mg/mL using serial dilutions calculated with C1V1 = C2V2. For example, to make 8 mg/mL from 10 mg/mL BSA stock: (10 mg/mL)(V1) = (8 mg/mL)(1000 μL) → V1 = 800 μL stock + 200 μL water. This systematic approach creates multiple concentration standards for building a reference curve.